Vicente Reynal
Chairman, President and Chief Executive Officer at Ingersoll Rand
Thanks, Vig. On Slide 13, 4th-quarter orders for ITS finished up 3% year-over-year and were approximately flat organically. Excluding the impact of China and the power tools and lifting business, Q4 organic orders grew low-single digits. Revenue finished down low-single digits organically with the largest impact coming from our China business. Our ITS segment delivered solid year-over-year adjusted EBITDA margin expansion of 30 basis-points on-top of near-record level margin from the prior year.
For the full-year, adjusted EBITDA margin finished at a record level of 30.2%, already meeting our 2027 targets three years ahead of schedule. Moving to the product-line highlights, compressor orders were up low-single digits, industrial vacuum and blower orders were up mid-teens and power tools and lifting orders were down mid-single digits. Highlighted here on our innovation in action is our new pure air oil-free compressor.
This product is a great example of Ingersoll Rand's multichannel, multi-brand strategy, providing an innovative, digitally-enabled sustainable solution with a market-leading 14% energy efficiency improvement. With 100% oil less technology, this product is perfect for applications which require FDA approval. Turning to Slide 14, orders in PSC were up 29% and revenue finished 24% year-over-year, largely driven by M&A. 4th-quarter organic orders finished slightly down year-over-year.
However, it is important to note that we did see low-single digit organic order growth excluding the impact of China. PST delivered adjusted EBITDA of $107 million, which was up approximately 14% year-over-year with a margin of 27.6%. The year-over-year decline in Q4 adjusted EBITDA margin was largely due to the impact of lower volumes in the Aerospace and defense business within the ILC Dover business as well as the flow-through related to organic volume declines primarily attributed to China. Important to note that PSP finished the full-year at approximately 30% adjusted EBITDA margin despite the organic growth headwinds. I would also like to take a minute to review some key highlights within our ILC Dover business. In the 4th-quarter, ILC Dover Life Science business grew revenue double-digits, which demonstrated their continued ability to deliver above-market growth.
Also, I am pleased to announce that in December, we reached a $150 million-plus multi-year agreement for our legacy business. This long-term deal has been incorporated in our 2025 guidance and we remain optimistic about the opportunities for growth within the Aerospace and defense business. For our PST innovation in action, we're highlighting a new diaphragm metering pump, which offers increased energy efficiency and 20% reduction in total cost of ownership. This is a perfect example of innovation, generating over $50 million of additional market opportunities in key markets that include water and wastewater. Moving to Page 15, we're introducing our 2025 guidance.
Total company revenue is expected to grow between 3% and 5%. We anticipate organic growth of 1% to 3% or price and volume are split 75% and 25%. FX is expected to be approximately a 2% headwind for the year. M&A is projected at $300 million, which reflects all completed and closed M&A transactions in 2024 as well as the acquisitions of SSI Ariation and Excelsio Blower systems discussed earlier. Corporate costs are planned at $165 million and are expected to be incurred evenly per quarter throughout the year. Total adjusted EBITDA for the company is expected to be in the range of $2.13 billion and $2.19 billion.
At the bottom of the table, adjusted EPS is projected to fall within the range of $3.38 and $3.50, which is approximately up 5% at the midpoint. We anticipate our adjusted tax-rate to be roughly 23%, net interest expense to be about $220 million and capex to be around 2% of revenue revenues. On the right-hand side of the page, we have included a 2025 full-year guidance bridge showing the growth associated with the operational activity and the impacts associated with FX, interest income and expense, tax-rate, corporate cost and share count.
On the next slide, we have provided some additional commentary regarding the phasing of our 2025 full-year guidance. So let me touch on a few key highlights. We expect total revenue growth to be consistent across both the first and the second-half of the year at approximately 3% to 5%. Consistent with what we have seen over the past few years, we expect sequential improvement throughout the year with Q1 being the lowest quarter in terms of revenue. To put a finer point on-Q1, we expect to see a very similar percentage decline in terms of revenue from Q4 '24 to-Q1 '25 to what we saw in the prior year. What that should equal to is low-single digit total revenue growth in the first-quarter. The 2025 phasing of both our revenue and adjusted EBITDA remains consistent with prior years. And this is illustrated on the right-hand side of the page showing both our historical revenue and adjusted EBITDA phasing since 2021 and our assumptions for 2025.
Finally, we expect adjusted EPS to follow the adjusted EBITDA phasing with a 46% to 54% split between the first and second-half of the year. Turning to Slide 17, is well-positioned for strong operational performance in 2025. We remain nimble and we're prepared to pivot in what continues to be a very dynamic global market environment. We continue to differentiate as an investment delivering double-digit revenue and adjusted EBITDA growth on average since 2020. To our employees, I want to thank you again for your part in delivering another record year. We delivered strong results by demonstrating our commitment to meeting our financial targets and executing our economic growth engine through the use of IRX. Today, our balance sheet remains stronger than ever, and we enter 2025 well-positioned to build upon our success to date. With that, I'll turn the call-back to the operator and open it for Q&A.